The Active Tumor Vaccination in Combination With CDK4/6 Inhibitor Treatment: A Case Report.
Anticancer Res
; 44(8): 3543-3550, 2024 Aug.
Article
de En
| MEDLINE
| ID: mdl-39060086
ABSTRACT
BACKGROUND:
Current standard treatment for metastatic breast cancer (MBC) involves cyclin-dependent kinase 4/6 (CDK4/6) inhibitors with endocrine therapy, showing potential in enhancing anti-tumor immune responses. CASE REPORT This report details a clinical case of MBC where palbociclib was co-administered with letrozole. The integration of allogeneic tumor vaccination to this treatment led to heightened interferon-γ production, expansion of CD8+ and NK cell populations, and positive delayed-type hypersensitivity reactions, indicating successful development of anti-tumor immunity. The induced production of interferon-γ by tumor vaccination was associated with manageable modulation of sensitivity to palbociclib-letrozole therapy. Administration of the BioNTech/Pfizer Covid-19 vaccine compromised the anti-tumor immune response by reducing cytotoxic cell populations and increasing immunosuppressive cytokine production. The patient undergoing combined treatment achieved a progressive-free survival of 42 months.CONCLUSION:
Incorporating active tumor vaccination with CDK4/6 inhibitor therapy presents a feasible approach for metastatic breast cancer. The precise regulation of the microenvironment emerges as a crucial factor and warrants careful consideration.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Pipérazines
/
Pyridines
/
Tumeurs du sein
/
Protocoles de polychimiothérapie antinéoplasique
/
Vaccins anticancéreux
/
Kinase-4 cycline-dépendante
/
Kinase-6 cycline-dépendante
Limites:
Female
/
Humans
/
Middle aged
Langue:
En
Journal:
Anticancer Res
/
Anticancer res
/
Anticancer research
Année:
2024
Type de document:
Article
Pays d'affiliation:
Israël
Pays de publication:
Grèce